Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease

GLIA

Volumn 64, Issue 3, 2016, Pages 386-395

  Martin, Heather L ^a   Santoro, Matteo ^a   Mustafa, Sarah ^a   Riedel, Gernot ^a   Forrester, John V ^a,b,c   Teismann, Peter ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c LIONS EYE INSTITUTE   (Australia)

Author keywords

MHCII; Microglia; MPTP; Neuroinflammation; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA; 3,4 DIHYDROXYPHENYLACETIC ACID; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA ANTIGEN CLASS 2; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BONE MARROW CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; MICROGLIA; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INTOXICATION; METABOLISM; PHYSIOLOGY; TIME FACTOR; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ADAPTIVE IMMUNITY; ANALYSIS OF VARIANCE; ANIMALS; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MPTP POISONING; RNA, MESSENGER; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84952985625     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22935     Document Type: Article

References (52)

1. Aloisi F, Ria F, Penna G, Adorini L. 1998. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 160:4671-4680.
2. Araneda S, Bobillier P, Buda M, Pujol JF. 1980. Retrograde axonal transport following injection of [3H]serotonin in the olfactory bulb. I. Biochemical study. Brain Res 196:405-415.
3. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. 2005. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11:493-498.
4. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA. 2011. alpha-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci 5:80.
5. Björklund H, Olson L, Dahl D, Schwarcz R. 1986. Short- and long-term consequences of intracranial injections of the excitotoxin, quinolinic acid, as evidenced by GFAP immunochemistry of astrocytes. Brain Res 371:267-277.
6. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. 2002. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 83:167-175.
7. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. 2009. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192.
8. Cardenas H, Bolin LM. 2003. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res 985:89-97.
9. Cresswell P. 1994. Antigen presentation. Getting peptides into MHC class II molecules. Curr Biol 4:541-543.
10. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. 1996. Microglial reaction in MPTP (1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5:137-143.
11. Dauer W, Przedborski S. 2004. Parkinson's disease: Mechanisms and models. Neuron 39:889-909.
12. Dong Y, Benveniste EN. 2001. Immune function of astrocytes. Glia 36:180-190.
13. Dong C, Flavell RA. 2001. Th1 and Th2 cells. Curr Opin Hematol 8:47-51.
14. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, Hunziker L, Suzuki S, Bachmaier K, Bingisser RM, Penninger JM, Kopf M. 2003. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 197:323-331.
15. Ferger B, Leng A, Mura A, Hengerer B, Feldon J. 2004. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89:822-833.
16. Hanisch UK. 2002. Microglia as a source and target of cytokines. Glia 40:140-155.
17. Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG. 2013. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33:9592-9600.
18. Hebert G, Arsaut J, Dantzer R, Demotes-Mainard J. 2003. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 349:191-195.
19. Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE. 1986. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol 136:3239-3245.
20. Hunot S, Hirsch EC. 2003. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53Suppl3:S49-S58; discussion S58-S60.
21. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. 2003. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106:518-526.
22. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4:257-269.
23. Jackson-Lewis V, Przedborski S. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2:141-151.
24. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. 1998. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Immunopharmacology 39:167-180.
25. Kreutzberg GW. 1996. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
26. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. 1999a. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50-61.
27. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. 1999b. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 59:1-8.
28. Lau AW, Biester S, Cornall RJ, Forrester JV. 2008. Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cells. J Immunol 180:3889-3899.
29. Luchtman DW, Shao D, Song C. 2009. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav 98:130-138.
30. Lynch MA. 2009. The multifaceted profile of activated microglia. Mol Neurobiol 40:139-156.
31. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
32. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. 1994a. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-150.
33. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. 1994b. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208-210.
34. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. 2007. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27:3328-3337.
35. Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett TA, Miller SD. 1997. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol 158:614-621.
36. Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A. 2013. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 3:1393-
37. Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, Rogers J, Beach TG, Cotman CW. 2007. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 28:1821-1833.
38. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
39. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. 2008. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131:1880-1894.
40. Prat A, Biernacki K, Wosik K, Antel JP. 2001. Glial cell influence on the human blood-brain barrier. Glia 36:145-155.
41. Ransom BR, Kunis DM, Irwin I, Langston JW. 1987. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 75:323-328.
42. Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, Ciborowski P, Banerjee R, Gendelman HE. 2008. Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 3:59-74.
43. Rohl C, Lucius R, Sievers J. 2007. The effect of activated microglia on astrogliosis parameters in astrocyte cultures. Brain Res 1129:43-52.
44. Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. 2015. The relation between alpha-synuclein and microglia in Parkinson's disease: Recent developments. Neuroscience 302:47-58.
45. Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S, Synofzik M, Vukovic Z, Itohara S, Berg D, Teismann P. 2012. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 135:3336-3347.
46. Shrikant P, Benveniste EN. 1996. The central nervous system as an immunocompetent organ: Role of glial cells in antigen presentation. J Immunol 157:1819-1822.
47. Takada M, Li ZK, Hattori T. 1990. Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death. Brain Res 509:55-61.
48. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. 1998. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol 160:4271-4279.
49. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S. 2003. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100:5473-5478.
50. West MJ. 1993. New stereological methods for counting neurons. Neurobiol Aging 14:275-285.
51. Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW. 1984. Inducible expression of H-2 and Ia antigens on brain cells. Nature 310:688-691.
52. Zhao J, Han X, Xue L, Zhu K, Liu H, Xie A. 2015. Association of TLR4 gene polymorphisms with sporadic Parkinson's disease in a Han Chinese population. Neurol Sci 36:1659-1665.